Key Events This Week
Jan 19: Stock opens at Rs.1,990.65, down 0.50%
Jan 20: Sharp decline to Rs.1,934.25 (-2.83%) amid heavy volume
Jan 21: Open interest surges 12.3%, price recovers slightly to Rs.1,943.35 (+0.47%)
Jan 22: Technical momentum shifts bullish, stock rallies 2.70% to Rs.1,995.90
Jan 23: Open interest spikes 18.25% despite 1.26% price decline to Rs.1,970.75
Monday, 19 January 2026: Modest Decline Amid Market Weakness
Glenmark Pharmaceuticals opened the week at Rs.1,990.65, down 0.50% from the previous close. The stock’s decline closely mirrored the Sensex’s 0.49% drop to 36,650.97, reflecting broad market weakness. Trading volume was moderate at 4,398 shares, indicating cautious investor participation as the market digested recent sector developments.
Tuesday, 20 January 2026: Sharp Price Drop on Heavy Volume
The stock experienced a significant decline of 2.83%, closing at Rs.1,934.25, on a surge in volume to 21,022 shares. This drop outpaced the Sensex’s 1.82% fall to 35,984.65, signalling stock-specific selling pressure. Delivery volumes increased by 32.7% compared to the five-day average, suggesting genuine investor exits rather than intraday speculation. The sharp fall set a cautious tone for the week’s trading.
Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!
- - Sustainable profitability reached
- - Post-turnaround strength
- - Comeback story unfolding
Wednesday, 21 January 2026: Renewed Optimism Evident in Derivatives Market
On 21 January, Glenmark Pharmaceuticals saw a notable 12.3% surge in open interest in its derivatives segment, rising to 52,415 contracts from 46,691. This increase accompanied a modest price recovery of 0.47%, with the stock closing at Rs.1,943.35. Trading volume in derivatives was robust at 35,035 contracts, with futures and options combined valued at over ₹1,25,213 lakhs. The rise in open interest alongside increased delivery volumes of 2.11 lakh shares indicated fresh capital inflows and renewed market optimism despite the broader sector’s 0.45% decline.
Technically, the stock remained above its 200-day moving average, a long-term bullish signal, though it was still below shorter-term averages, suggesting consolidation. The stock outperformed the Sensex, which fell 0.47% that day, highlighting relative strength amid market volatility.
Technical Momentum Shifts Amid Mixed Signals
Alongside the derivatives activity, technical indicators showed a shift from bullish to mildly bullish momentum. The MACD was mildly bearish on the weekly chart but bullish monthly, while the RSI hovered neutrally. Bollinger Bands suggested increased volatility with bearish weekly but mildly bullish monthly readings. The stock’s price remained above key daily moving averages, supporting a cautiously optimistic outlook. Despite short-term underperformance versus the Sensex, Glenmark’s long-term returns remain strong, with a 1-year gain of 28.16% compared to the Sensex’s 6.63%.
Thursday, 22 January 2026: Bullish Technical Momentum Spurs Rally
Glenmark Pharmaceuticals rallied 2.70% to close at Rs.1,995.90, its highest level of the week, supported by a shift to a more confident bullish technical trend. The stock traded between Rs.1,951.85 and Rs.2,005.00, demonstrating healthy volatility within an upward trajectory. Key indicators such as the MACD turned bullish on both weekly and monthly charts, while daily moving averages aligned positively, confirming the uptrend.
The Relative Strength Index remained neutral, indicating room for further gains without immediate overbought risk. Bollinger Bands on weekly and monthly charts were mildly bullish, suggesting controlled price expansion. On-Balance Volume readings supported accumulation, reinforcing the bullish momentum. This technical strength contrasted with the Sensex’s 0.76% gain, underscoring Glenmark’s sector leadership.
Curious about Glenmark Pharmaceuticals Ltd. from ? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Friday, 23 January 2026: Open Interest Surges Amid Price Decline
Despite a 1.26% decline to Rs.1,970.75, Glenmark Pharmaceuticals saw an 18.25% surge in open interest in its derivatives segment, rising to 52,795 contracts from 44,648. Daily volume remained strong at 30,059 contracts, with futures and options combined valued at over ₹1,38,856 lakhs. Delivery volumes spiked dramatically to 5.15 lakh shares, a 223.51% increase over the five-day average, signalling strong investor conviction despite short-term price weakness.
The stock traded below its 5-day and 20-day moving averages but remained above longer-term averages, indicating near-term consolidation within a sustained uptrend. The price underperformed the Sensex’s 1.33% decline, reflecting mixed market sentiment. The elevated derivatives activity suggests traders are positioning for a potential directional move, balancing bullish fundamentals against short-term technical caution.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-01-19 | Rs.1,990.65 | -0.50% | 36,650.97 | -0.49% |
| 2026-01-20 | Rs.1,934.25 | -2.83% | 35,984.65 | -1.82% |
| 2026-01-21 | Rs.1,943.35 | +0.47% | 35,815.26 | -0.47% |
| 2026-01-22 | Rs.1,995.90 | +2.70% | 36,088.66 | +0.76% |
| 2026-01-23 | Rs.1,970.75 | -1.26% | 35,609.90 | -1.33% |
Key Takeaways
Relative Outperformance: Glenmark Pharmaceuticals declined 1.49% over the week, outperforming the Sensex’s 3.31% fall, highlighting relative strength amid broader market weakness.
Derivatives Market Activity: Sharp surges in open interest on 21 and 23 January (12.3% and 18.25% respectively) accompanied by elevated volumes indicate strong investor engagement and positioning for potential directional moves.
Technical Momentum Shifts: The stock’s technical profile evolved from mildly bullish to bullish midweek, supported by positive MACD and moving averages, though short-term volatility and mixed signals warrant cautious monitoring.
Volume and Delivery Trends: Significant increases in delivery volumes on 20 and 22 January suggest genuine accumulation and investor conviction despite price fluctuations.
Mojo Score Upgrade: Glenmark’s MarketsMOJO score improved to 91.0 with a Strong Buy grade, reflecting enhanced fundamentals and positive analyst sentiment.
Conclusion
This week’s trading in Glenmark Pharmaceuticals was characterised by a complex interplay of cautious price declines, robust derivatives activity, and evolving technical momentum. While the stock ended the week lower by 1.49%, it outperformed the broader market, supported by strong open interest growth and delivery volume spikes that signal underlying investor confidence. The technical indicators suggest a bullish trend gaining traction, though short-term volatility and mixed signals advise prudence. Glenmark’s upgraded mojo rating and relative resilience within the Pharmaceuticals & Biotechnology sector position it as a noteworthy stock amid ongoing market fluctuations. Investors should continue to monitor technical developments and derivatives market activity closely to gauge the sustainability of this emerging trend.
Unlock special upgrade rates for a limited period. Start Saving Now →
